Clinical trial
Geldanamycin Analogue in Treating Patients With Advanced Cancer
NCT00003969 · Cancer Research UK, Other · Completed
Key facts
| NCT number | NCT00003969 |
|---|---|
| Title | Geldanamycin Analogue in Treating Patients With Advanced Cancer |
| Official title | A Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino-17-Demethoxygeldanamycin (17-AAG) (NSC 330507) Via Intravenous Administration in Patients With Advanced Malignancies |
| Lead sponsor | Cancer Research UK, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | tanespimycin |
| Start date | Aug 1, 1998 |
| Completion | Jan 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 26, 2013 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: